Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aticaprant (LY-2456302) (CERC-501) is a potent and centrally-penetrant antagonist of the kappa-opioid receptor (Ki: 0.807 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
2 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 80.00 | |
10 mg | In stock | $ 128.00 | |
25 mg | In stock | $ 272.00 | |
50 mg | In stock | $ 428.00 | |
100 mg | In stock | $ 639.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 89.00 |
Description | Aticaprant (LY-2456302) (CERC-501) is a potent and centrally-penetrant antagonist of the kappa-opioid receptor (Ki: 0.807 nM). |
Targets&IC50 | κ opioid:0.807 nM (Ki) |
In vitro | Aticaprant binds with a high affinity to the human kappa opioid receptor with a 30-fold higher affinity over the human mu-opioid receptor and a 190-fold higher affinity over the human delta-opioid receptor. Aticaprant shows no appreciable affinity for several non-opioid cell surface G-protein-coupled receptor targets [1]. |
In vivo | Aticaprant has rapid absorption (tmax=1-2 h) and good oral bioavailability (F=25%). Aticaprant selectively and potently occupies central kappa opioid receptors (ED50: 0.33 mg/kg, p.o.), without evidence of mu or delta receptor occupancy. LY2456302 potently blocks kappa-agonist-mediated analgesia and disruption of prepulse inhibition, without affecting mu-agonist-mediated effects at doses >30-fold higher. Aticaprant produces antidepressant-like effects in the mouse forced swim test and enhances the effects of imipramine and citalopram. Aticaprant reduces ethanol self-administration in alcohol-preferring rats [1]. Aticaprant alleviates the nicotine withdrawal syndrome, as evidenced by decreased expression of nicotine withdrawal-induced anxiety-related behavior, somatic signs, and CPA, and increased hotplate latency in nicotine withdrawn mice following pre-treatment [2]. |
Animal Research | Three male cannulated rats are administered a single 1 mg/kg intravenous (IV) and 10 mg/kg oral (PO) dose of Aticaprant to determine the pharmacokinetic parameters. Plasma samples are collected at 0.08 (IV only), 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h post-dose and analyzed by liquid chromatography coupled to tandem mass spectral detection to determine the concentrations of Aticaprant (CERC-501). Male mice are administered a single 10 mg/kg PO dose of Aticaprant to determine the pharmacokinetic parameters. Plasma samples are collected at 0.5, 1, 2, 4, 8, and 24 h post-dose and analyzed by LCMS/MS to determine the concentrations of Aticaprant. The plasma and brain binding of Aticaprant is determined by equilibrium dialysis at 1 μM [1]. |
Synonyms | LY-2456302, CERC-501 |
Molecular Weight | 418.5 |
Formula | C26H27FN2O2 |
CAS No. | 1174130-61-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (238.95 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Aticaprant 1174130-61-0 Endocrinology/Hormones GPCR/G Protein Neuroscience Opioid Receptor inhibit LY-2456302 CERC501 Inhibitor CERC 501 CERC-501 LY2456302 LY 2456302 inhibitor